QNTM:NASDAQQuantum Biopharma Ltd. Analysis
Data as of 2026-09-08 - not real-time
$3.24
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $3.24, Quantum BioPharma Ltd. shows no decisive moving-average alignment, leaving the trend neutral. Across the trailing 30 sessions it gained 8.4%. With RSI at 49.8 the momentum picture is neutral, alongside a bearish MACD signal. The recent range runs from support at $2.91 up to resistance at $4.20.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 290.4% above where the shares trade now.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 91.0%, a beta of 0.70 and a maximum drawdown of 89.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons diverge: sell near-term but hold on a long view, at 3/10 conviction over the longer horizon.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 290.4% above where the shares trade now.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 91.0%, a beta of 0.70 and a maximum drawdown of 89.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons diverge: sell near-term but hold on a long view, at 3/10 conviction over the longer horizon.
Top Market Events
Austin, Texas, August 10th, 2026, FinanceWireThis article has been disseminated on behalf of Quantum BioPharma Ltd.Austin, Texas, August 13th, 2026, FinanceWireThis article has been disseminated on behalf of Quantum BioPharma Ltd.Biomednewsbreaks - Quantum Biopharma Ltd.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Trading below the 200-day average of 4.90
- MACD momentum is negative
- 30-day price change of +8.4%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 4.90
- Analyst targets imply +290.4% versus the current price
- 30-day volatility of 91.0%
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- Analyst targets imply +290.4% versus the current price
- Negative return on equity of -621.5%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-0.4
ROE-621.46%
ROA-51.84%
Debt/Equity15.81
P/B Ratio3.1
Op. Cash Flow$-5485545
Free Cash Flow$-5031993
Industry P/E30.6
Technical Analysis
TrendNeutral
RSI49.8
Support$2.91
Resistance$4.20
MA 20$3.31
MA 50$3.26
MA 200$4.90
MACDBearish
VolumeDecreasing
Fear & Greed Index93.23
Valuation
Target Price$12.65
Upside/Downside290.39%
GradeFair
TypeBlend
Risk Assessment
Beta0.70
Volatility91.04%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.